IGC Receives New Patent from U.S. Patent Office to Treat Cachexia and Eating Disorders in Humans and Veterinary Animals - IGC Pharma, INC.

Press

Releases

March 26, 2020

IGC Receives New Patent from U.S. Patent Office to Treat Cachexia and Eating Disorders in Humans and Veterinary Animals

Related Posts

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

November 3, 2025

IGC Pharma Advances to Semi-Finals in the Alzheimer’s Insights AI Prize with “AHA: Agentic Harmonization Assistant”

October 22, 2025

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida’s Department of Psychiatry and Behavioral Neurosciences

October 14, 2025

CEO Update

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

November 3, 2025

IGC Pharma Advances to Semi-Finals in the Alzheimer’s Insights AI Prize with “AHA: Agentic Harmonization Assistant”

October 22, 2025